The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease

American Journal of Clinical Nutrition

Volumn 96, Issue 3, 2012, Pages 516-526

  Van Borst, Bram Den ^a   Gosker, Harry R ^a   Koster, Annemarie ^a,b   Yu, Binbing ^b   Kritchevsky, Stephen B ^c   Liu, Yongmei ^c   Meibohm, Bernd ^d   Rice, Thomas B ^e   Shlipak, Michael ^f   Yende, Sachin ^g   Harris, Tamara B ^b   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; FEMALE; FOOD INTAKE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LUNG FUNCTION TEST; MALE; MORTALITY; NUTRITIONAL ASSESSMENT; PHYSICAL ACTIVITY; PREDICTIVE VALUE; RISK ASSESSMENT; SMOKING; SURVIVAL TIME;

ADIPONECTIN; AGED; DIET; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MATCHED-PAIR ANALYSIS; MOTOR ACTIVITY; PENNSYLVANIA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREVALENCE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK; TENNESSEE;

EID: 84865321696     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.040774     Document Type: Article

References (53)

1. Gooneratne NS, Patel NP, Corcoran A. Chronic obstructive pulmonary disease diagnosis and management in older adults. J Am Geriatr Soc 2010;58:1153-62.
2. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011;5:647-62.
3. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55.
4. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009;68:370-7.
5. van den Borst B, Gosker HR, Wesseling G, de Jager W, Hellwig VA, Snepvangers FJ, Schols AM. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. Am J Clin Nutr 2011;94:1504-12.
6. Koenen TB, Stienstra R, van Tits LJ, Joosten LA, van Velzen JF, Hijmans A, Pol JA, van der Vliet JA, Netea MG, Tack CJ, et al. The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology 2011;152:3769-78.
7. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83: 847-50.
8. Furutate R, Ishii T, Wakabayashi R, Motegi T, Yamada K, Gemma A, Kida K. Excessive visceral fat accumulation in advanced chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6: 423-30.
9. Kuk JL, Lee S, Heymsfield SB, Ross R. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005;81:1330-4.
10. Sugihara M, Oka R, Sakurai M, Nakamura K, Moriuchi T, Miyamoto S, Takeda Y, Yagi K, Yamagishi M. Age-related changes in abdominal fat distribution in Japanese adults in the general population. Intern Med 2011;50:679-85.
11. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev 2011;10:319-29.
12. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-6.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
14. Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB, Meibohm B. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol 2010;20:223-32.
15. van den Borst B, Koster A, Yu B, Gosker HR, Meibohm B, Bauer DC, Kritchevsky SB, Liu Y, Newman AB, Harris TB, et al. Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking? Thorax 2011;66:961-9.
16. Snijder MB, Visser M, Dekker JM, Seidell JC, Fuerst T, Tylavsky F, Cauley J, Lang T, Nevitt M, Harris TB. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord 2002;26:984-93.
17. Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM, Visser M, Houston DK, Nicklas BJ, Tylavsky FA, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010;18:2354-61.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
20. Lee JS, Kritchevsky SB, Tylavsky FA, Harris T, Everhart J, Simonsick EM, Rubin SM, Newman AB. Weight-loss intention in the well-functioning, community-dwelling elderly: associations with diet quality, physical activity, and weight change. Am J Clin Nutr 2004;80:466-74.
21. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011;42. Available from: http://www.jstatsoft.org/v42/i07.
22. Ming K, Rosenbaum PR. Substantial gains in bias reduction from matching with a variable number of controls. Biometrics 2000;56:118-24.
23. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008;27:2037-49.
24. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-73.
25. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046-51.
26. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, O'Connor GT, Benjamin EJ. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008;133:19-25.
27. Breyer MK, Rutten EP, Vernooy JH, Spruit MA, Dentener MA, van der Kallen C, Vangreevenbroek MM, Wouters EF. Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin. Respir Med 2011;105:1046-53.
28. Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, Ghanei M, Basiri R. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:335-40.
29. He Z, Chen Y, Chen P, Wu G, Cai S. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 2010;15: 478-84.
30. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11:63.
31. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-72.
32. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010;77:550-6.
33. Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg 2010;51:1498-503.
34. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.
35. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
36. Poehls J, Wassel CL, Harris TB, Havel PJ, Swarbrick MM, Cummings SR, Newman AB, Satterfield S, Kanaya AM. Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study. Diabetologia 2009;52:591-5.
37. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723-30.
38. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
39. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599-606.
40. Walkey AJ, Rice TW, Konter J, Ouchi N, Shibata R, Walsh K, deBoisblanc BP, Summer R. Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care Med 2010;38:2329-34.
41. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease: a prospective cohort study. Chest 2011;140:331-42.
42. Kovacova Z, Tencerova M, Roussel B, Wedellova Z, Rossmeislova L, Langin D, Polak J, Stich V. The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes (Lond) 2011;Dec 06 (Epub ahead of print; DOI:10.1038/ijo.2011.223).
43. Miller M, Cho JY, Pham A, Ramsdell J, Broide DH. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 2009;182:684-91.
44. Zhu M, Hug C, Kasahara DI, Johnston RA, Williams AS, Verbout NG, Si H, Jastrab J, Srivastava A, Williams ES, et al. Impact of adiponectin deficiency on pulmonary responses to acute ozone exposure in mice. Am J Respir Cell Mol Biol 2010;43:487-97.
45. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9.
46. Van Berendoncks AM, Conraads VM. Functional adiponectin resistance and exercise intolerance in heart failure. Curr Heart Fail Rep 2011;8:113-22.
47. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 2004;47:816-20.
48. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, et al. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 2010; 3:185-94.
49. Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, Bouillon R, Decramer M. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:1105-11.
50. Zafon C. Fat and aging: a tale of two tissues. Curr Aging Sci 2009;2:83-94.
51. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, Tracy R, Szklo M, Bathon JM. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010;62:3173-82.
52. Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, Klibanski A. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab 2003;88:5468-72.
53. Balci A, Balci DD, Yonden Z, Korkmaz I, Yenin JZ, Celik E, Okumus N, Egilmez E. Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 2010;220:32-7.